Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

Sponsor

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT02533765

Collaborator

(none)

Enrollment

Locations

Arm

68.7

Anticipated Duration (Months)

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is open-label, single-arm, two-stage phase II trial of olaparib in patients with relapsed/refractory metastatic germ cell cancer. The primary objective is to evaluate the preliminary activity of Olaparib in GCT tumors. The secondary objective is to evaluate the safety of Olaparib in patients with cisplatin-refractory GCT.

Condition or Disease	Intervention/Treatment	Phase
Neoplasms, Germ Cell and Embryonal	Drug: Olaparib	Phase 2

Detailed Description

This is a proof-of principle open-label, single-arm, two-stage phase II trial of olaparib 300 mg twice daily in patients with relapsed/refractory metastatic germ cell cancer. The study will recruit 10 patients, if no response is seen the study is terminated. If one or more responses are observed, further 19 patients (for a total of 29 patients) will be enrolled. If 4 or more of the first 29 evaluable patients have achieved objective response, further studies in patients with metastatic germ cell cancer are warranted.

The main inclusion criteria are:

Patient with metastatic gonadal GCT or extragonadal GCT originating from retroperitoneum or mediastinum.
Disease progression during cisplatin-based chemotherapy or disease progression or relapse after high-dose chemotherapy or disease progression or relapse after at least 2 different cisplatin-based regimens
At least one measurable lesion that can be accurately assessed by CT/MRI/plain x-ray) at baseline and follow up visits.

The study will be analyzed on an intent-to-treat basis. Secondary parameters will be analyzed exploratively for the intent-to-treat population.

Correlations between with biomarkers (PAR, poly adenosine diphosphate-ribose polymerase (PARP-1), PTEN, XPA, ERCC1-3, XPF, FanD2, γ-H2AX) expression in paraffin-embedded tumor samples and clinical outcome will be performed in an exploratory intent. Plasma samples will be collected at baseline and at response/progression for possible retrospective biomarkers study.

Study Design

Study Type:

Interventional

Actual Enrollment :

18 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

Actual Study Start Date :

Sep 11, 2015

Actual Primary Completion Date :

Sep 1, 2018

Anticipated Study Completion Date :

Jun 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Olaparib Olaparib 300mg twice daily continuously	Drug: Olaparib Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study. Other Names: AZD2281

Arm

Intervention/Treatment

Experimental: Olaparib

Olaparib 300mg twice daily continuously

Drug: Olaparib

Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.

Other Names:

AZD2281

Outcome Measures

Primary Outcome Measures

Overall Response Rate (ORR) [Up to 30 months]
The percentage of patients whose cancer achieve either a partial response or a complete response.Tumor response will be assessed using CT scan or MRI of chest/abdomen using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and by tumor marker (AFP, betaHCG, LDH) measurements

Secondary Outcome Measures

Evaluation of number, type and grade of Adverse Events [Up to 30 months]
All patients will be evaluable for toxicity from the time of their first treatment with Olaparib
Progression free survival (PFS) [Up to 30 months]
time from the date of starting of the treatment to the date of the first observation of documented disease progression or death due to any cause. Patients without tumor progression at the time of analysis will be censored at their last date of tumor evaluation.
Overall survival (OS) [Up to 30 months]
Time from enrolment to the date of death due to any cause. For subjects with no known date of death, survival time will be censored at the date of their last on-study assessment.
exploratory analysis of the association between PFS or OS and biomarkers [Up to 30 months]
correlation between biomarkers (PAR, PARP-1, PTEN, XPA, ERCC1-3, XPF, FanD2, γ-H2AX) in paraffin-embedded tumor samples and plasma with clinical outcome (response, PFS, OS)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion criteria:

Patients ≥ 18 years old
Histologically verified metastatic gonadal GCT or extragonadal GCT originating from retroperitoneum or mediastinum.
Disease progression during cisplatin-based chemotherapy or disease progression or relapse after high-dose chemotherapy or disease progression or relapse after at least 2 different cisplatin-based regimens
patients who progressed during cisplatin-based therapy and who are not eligible for high-dose chemotherapy
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2
Life expectancy ≥3 months
At baseline adequate function of liver, kidneys and bone marrow

Neutrophils ≥ 1500 /mm3;
Hemoglobin ≥ 9.0 g/dL;
Platelets ≥ 80 x109/L;
Creatinine ≤ 1.5x upper limit of normal (ULN) In case of liver metastases increased levels of the following three parameters is acceptable:
Bilirubin ≤ 1.5 x ULN
serum glutamate oxaloacetate transaminase (SGOT (AST) ≤2.5 x ULN
serum glutamate pyruvate transaminase (SGPT (ALT) < 2.5 x ULN;

Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to International Conference on Harmonization Good Clinical Practice (ICH GCP), and national/local regulations.Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
At least one measurable lesion that can be accurately assessed by CT/MRI/plain x-ray) at baseline and follow up visits.

Exclusion criteria:

Systemic antitumor treatment within 21 days before study entry
Simultaneous radiotherapy to the only target lesion
Patients with resting ECG with QTc > 470 msec detected on 2 or more time points within a 24 hour period or family history of long QT syndrome. If ECG demonstrates QTc >470 msec, patient will be eligible only if repeat ECG demonstrates QTc ≤470 msec
Patients who have experienced a seizure or seizures within 6 months of study treatment or who are currently being treated with cytochrome P450 enzyme inducing anti-epileptic drugs for seizures.
Patients with uncontrolled brain metastases.
Patients receiving prohibited classes of inhibitors of CYP3A4 (see section 6.5.1).
Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
Patients with any acute toxicities due to previous cancer treatment that have not resolved to a Common Toxicity Criteria for Adverse Effects (NCI-CTCAE v 4.03) grade 0 or 1 with the exception of chemotherapy induced alopecia and grade 2 peripheral neuropathy.
Patients affected by myelodysplastic syndrome or acute myeloid leukemia
Known to be serologically positive for HIV and receiving antiretroviral therapy
Known seropositive for active viral infection with hepatitis B virus (HBV) (patients who are HBsAg negative, anti-HBs positive and/or hepatitis B core antigen (Anti-HBc) positive, but viral DNA negative are eligible)
Known seropositive for active infection with hepatitis C virus (HCV)
Patients unwilling or unable to comply with the protocol
Patients with unstable angina pectoris, myocardial infarction ≤ 6 months prior to first study treatment, congestive heart failure New York Heart Association (NYHA) III-IV or serious uncontrolled cardiac arrhythmias
Patients with an active or uncontrolled infection
Patients who have a history of another primary malignancy and are off treatment for ≤ 3 years, with the exception of non-melanoma skin cancer
Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g. intra-thoracic, intra-abdominal, or intra-pelvic) or significant traumatic injury, or who have not recovered from the side effects of any of the above within 6 weeks
Patients who have participated in another interventional clinical trial within 30 days before study entry
Other serious medical conditions that could impair the ability of the patient to participate in the study
Active infection requiring systemic antibiotic-, anti-viral-, or anti-fungal medication
Active cancer (other than GCT) including prior malignancy from which the patient has been disease-free for ≤3 years (except superficial basal cell skin cancer)
Patients with a known hypersensitivity to the combination/comparator agent
Patients with uncontrolled seizures.